NCT07441395Phase 2Recruiting

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

Study sponsor: Corvus Pharmaceuticals, Inc. · CRVS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants200Estimated

Source updated2026-03-05Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-05 · 2 fields changed

Primary completion date changed

− Before

~~Aug 2027~~

+ After

Jun 2027

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Atopic Dermatitis; Atopic Dermatitis Eczema; Eczema; Eczema, Atopic

Treatments or interventions studied

SoquelitinibDrugAlso known as CPI-818
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12; description: EASI is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head and neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.; timeFrame: Baseline through Week 12

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history